Phase 2Recruiting

Mindfulness-based Psilocybin Therapy for PTSD

A Pilot Mechanistic RCT of Psilocybin With Mindfulness-based Therapy vs Support for Posttraumatic Stress Disorder (PTSD)

Sponsor
Anthony P King (Academic or other)
Enrollment
30 planned
Conditions
Post Traumatic Stress Disorder; Depression - Major Depressive Disorder
Interventions
Psilocybin + MBCT therapy; Active Comparator: Psilocybin with Support Only
Ages
adults, older adults
Registry
NCT07104916

Full record on ClinicalTrials.gov

From the registry

The goal of this study is to learn how psilocybin delivered with mindfulness-based therapy may help symptoms of posttraumatic stress disorder (PTSD). This is an assessor-blinded, randomized, controlled study in participants with PTSD. The study will investigate the changes in brain activity, connectivity, and microstructural neuroplasticity assessed using EEG/EMG and multimodal MRI measures after administration of one oral dose of psilocybin, accompanied either with standard "psychological support" only; or with standard support plus Mindfulness-based Cognitive Therapy (MBCT).

Primary outcomes

  • Changes in parameter estimate of regional brain activity measured by fMRI after one dose of psilocybin in participants with PTSD
  • Changes in region-to-region connectivity measured by fMRI after PAT with one dose of psilocybin in patients with PTSD
  • Changes in event related potentials (ERP) after PAT with one dose of psilocybin in participants with PTSD
  • Changes in acoustic startle electromyographic (EMG) response after PAT with one dose of psilocybin in patients with PTSD

History

  1. Study completion expected

  2. Primary completion expected

  3. Last registry update

  4. Started

  5. Registered